生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Betaxolol hydrochloride (BH) is a cardioselective betaadrenergic receptor blocking agent used in the treatment of hypertension and glaucoma[3]. Betaxolol inhibited specific [3H]-batrachotoxinin-A 20-α-benzoate ([3H]-BTX-B) binding to neurotoxin site 2 in a concentration-dependent manner with an IC50 value of 9.8 μM. Betaxolol inhibited veratridine-stimulated Na+ influx in rat cortical synaptosomes with an IC50 value of 28.3 μM[4]. Moreover, the anxiolytic-like effect of betaxolol on cocaine-induced anxiety may be related to its effect on amygdalar beta(1)-adrenergic receptors that are up-regulated during early phases of drug withdrawal[5]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01316952 | - | Completed | - | - | |
NCT02617459 | Primary Open-angle Glaucoma ... 展开 >> Ocular Hypertension 收起 << | Phase 3 | Unknown | November 2016 | China, Guangdong ... 展开 >> Zhongshan ophthalmic center, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Jian Ge, MD 0+86-20-87330000 Principal Investigator: Jian Ge, MD 收起 << |
NCT00000132 | Open-Angle Glaucoma | Phase 3 | Unknown | - | Sweden ... 展开 >> Department of Ophthalmology, Helsingborg Hospital Helsingborg, Sweden Department of Ophthalmology, Malmo University Hospital, University of Lund Malmo, Sweden 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.91mL 0.58mL 0.29mL |
14.54mL 2.91mL 1.45mL |
29.08mL 5.82mL 2.91mL |
参考文献 |
---|